Kornimate/medical-research-clean huggingface dataset:
post acute sequelae of covid-19

Conditions: Covid19; Sars-CoV-2 Infection; Dyspnea Caused by 2019-nCoV; COVID-19 Acute Respiratory Distress Syndrome; Pulmonary Fibrosis

Summary: covid-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. there is ongoing research and growing literature describing severe acute respiratory syndrome (sars-cov-2). there is a growing population of individuals who have recovered from acute sars-cov-2 infection. the long-term effects of covid-19 are unknown. there are growing reports of sequelae after acute sars-cov-2 not limited to fatigue, dyspnea, reactive airway disease, organizing pneumonia, pulmonary fibrosis, pulmonary hypertension, pulmonary emboli, and tracheal disease. the incidence and natural history of these findings is unstudied.

covid-19 is a leading cause of death worldwide. the long-term effects of the virus are unknown. there is lack of reliable information about the natural history of post acute sequelae. although there are limited evidence-based treatment guidelines, many patients receive unproven therapies. given the mortality and morbidity associated with the illness and the growing number of patients who have survived covid-19 the long-term effects are a growing area of inquiry. this study is designed to better understand the effects of sars-cov-2 that develop over time. this study will characterize the recovery process, epidemiology, and natural history of post-acute sequelae. this includes the clinical spectrum of recover and subsets of patients who have symptoms outside the standard course. factors studied will include the individual, clinical context, severity of disease, duration of symptoms and the impact of treatment for acute sars-cov-2. this study will include a breadth of severity from those treated as outpatients, those requiring hospitalization, and those requiring critical care. key personnel will extract data recorded in the electronic health record (ehr) as part of routine clinical care in the evaluation in treatment of covid-19 and its sequelae. data such as incidence, prevalence, demographics, comorbidities, duration of illness, severity, level of medical care, measures of organ function, drug treatments, laboratory values, pulmonary function tests, computed tomography images, and other data from clinical care will be retrospectively entered into electronic data capture (redcap).

Eligibility criteria:
inclusion criteria: * 18 years or older * covid-19 diagnosis * seen in a vanderbilt clinic or affiliated health facility exclusion criteria: * none
combination chemotherapy in treating patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic colorectal cancer that has not responded to previous chemotherapy.

objectives: i. determine the efficacy of oxaliplatin, leucovorin calcium, and fluorouracil followed by irinotecan, leucovorin calcium, and fluorouracil in terms of progression free survival in patients with metastatic colorectal cancer. ii. evaluate these treatment regimens in terms of overall survival, response rate, toxicity, and quality of life in this patient population. outline: this is a multicenter study. patients receive 4 courses of oxaliplatin iv and leucovorin calcium iv over 2 hours on day 1 followed by fluorouracil iv continuously over 46 hours. following the initial 4 courses of therapy, patients receive 4 courses of irinotecan iv over 30-90 minutes and leucovorin calcium iv over 2 hours on day 1 followed by fluorouracil iv continuously over 46 hours. courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. quality of life is assessed every 8 weeks. patients are followed every 3 months until death. projected accrual: a total of 14-39 patients will be accrued for this study over 12 months.

Eligibility criteria:
disease characteristics: histologically confirmed metastatic adenocarcinoma of the colon or rectum measurable or evaluable lesion or residual disease (e.g., ascites, bone metastases) failure after first line therapy fluorouracil and leucovorin calcium or raltitrexed no oxaliplatin or irinotecan relapse within 6 months of adjuvant therapy relapse within 6 months of hepatic artery infusion chemotherapy for resected hepatic metastasis no symptomatic brain metastasis patient characteristics: age: 18 to 80 performance status: who 0-2 life expectancy: at least 3 months hematopoietic: absolute neutrophil count at least 1,500/mm3 hepatic: ast and alt no greater than 3 times upper limit of normal (uln) alkaline phosphatase no greater than 5 times uln renal: not specified other: no bowel obstruction no other significant, uncontrolled underlying medical or psychiatric condition no serious active infection neurologically stable no other prior malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix no psychological, social, familial, or geographical condition that would preclude study not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: at least 2 weeks since prior radiotherapy surgery: at least 2 weeks since prior surgery other: no other concurrent experimental drugs

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
acute kidney injury in coronavirus disease-19 (covid-19) patients admitted to the intensive care unit (icu)

Conditions: Critical Illness; COVID-19 Pneumonia; Acute Kidney Injury

Summary: the aim of this study is to evaluate the rate and outcomes of covid-19 associated acute kidney injury (aki) and use of kidney replacement therapy (krt) in critically ill covid-19 patients in icus in several large hospitals in flanders, the northern region of belgium. we will also explore the associations between several baseline risk factors for aki, therapeutic strategies and covid-19 related clinical signs and the occurrence of aki and use of krt.

the aim of this study is to evaluate the rate and outcomes of covid-19 associated acute kidney injury (aki) and use of kidney replacement therapy (krt) in critically ill covid-19 patients in icus in several large hospitals in flanders, the northern region of belgium. we will also explore the associations between several baseline risk factors for aki, therapeutic strategies and covid-19 related clinical signs and the occurrence of aki and use of krt. this will be a cohort analysis of the rate of covid-19 associated aki and krt during the period 1 february 2020 - 31 january 2021 in 6 large hospitals in flanders belgium and 3 flemish university hospitals. we will collect patients' baseline characteristics, specific treatment for covid-19, other relevant therapies and severity of illness and icu and hospital outcome data. aki will be assessed during icu stay up to 21 days of icu stay, and will be defined according to the kidney disease: improving global outcomes (kdigo) definition. in addition, we will assess occurrence of aki stages, duration of aki, duration of aki integrated with severity stage of aki into the area under the curve of aki, occurrence of rapid reversal of aki, occurrence of acute kidney disease (akd) defined according to kdigo.

Eligibility criteria:
inclusion criteria: * severe acute respiratory syndrome coronavirus-2 (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) on nasopharyngeal swab or oropharyngeal swab or rectal swab or bronchoalveolar aspirate * admission to the icu for monitoring or organ support exclusion criteria: * asymptomatic covid-19 patients admitted to the icu for medical reason not related to covid-19

Keywords: acute kidney injury covid-19 icu epidemiology kidney replacement therapy acute kidney disease recovery mortality survival
safety, efficacy and pk/pd of pol7080 in patients with exacerbation of non-cystic fibrosis bronchiectasis.

Conditions: Bronchiectasis; Lower Respiratory Infection

Summary: to test whether pol7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by pseudomonas aeruginosa infection.

* patients will be recruited after written informed consent. * adverse events will be coded using medical dictionary for regulatory activities (meddra). * descriptive statistics will be used for all the safety and efficacy variables.

Eligibility criteria:
inclusion criteria: 1. male and female aged ≥18 to \<80 years and suffering from exacerbation of non-cystic fibrosis bronchiectasis due to pseudomonas aeruginosa infection 2. sputum sample collected for culture before starting treatment exclusion criteria: 1. female patients who are pregnant or breast feeding or unwilling to follow reliable method of contraception 2. subjects suffering from cystic fibrosis, active pulmonary mycobacterial infection, end stage chronic obstructive pulmonary disease on long term oxygen therapy, severe uncontrolled asthma, active sarcoidosis and active allergic broncho-pulmonary aspergillosis 3. current exacerbation of bronchiectasis is associated with lung abscess or empyema 4. current exacerbation episode is suspected or documented to be due to pathogens other than pseudomonas aeruginosa 5. patients with known hiv infection with cd4+ (cluster of differentiation 4) cell count \< 200/mm3 6. patients who are currently enrolled in, or have not yet completed at least 30 days since ending another investigational device or drug trial or are receiving other investigational agent

Keywords: pol7080 pseudomonas aeruginosa non cystic fibrosis bronchiectasis exacerbation
android artificial pancreas system (android aps) versus control-iq

Conditions: Diabetes Mellitus, Type 1

Summary: the aim of the investigator's study is to compare two different closed loop hybrid systems - certified control-iq and noncertified androidaps in adult patients with type 1 diabetes (t1d), who had been using androidaps previously from their own decision, during 12 weeks of follow-up.


Eligibility criteria:
inclusion criteria: * type 1 diabetes diagnosed \>2 years * ≥ 18 years old * written informed consent prior to starting study related activity * previous user of androidaps at least for 3 months exclusion criteria: * severe noncompliance * lactation, pregnancy, intending to become pregnant during study * use of medication with effects on carbohydrate metabolism

Keywords: continuous glucose monitoring insulin pump closed-loop hybrid system
image-guided adaptive radiotherapy for cervix cancer: patient image acquisition

Conditions: Cervix Cancer

Summary: within this study patient data are collected from different imaging and motion monitoring devices that will be used to develop and test strategies for image-guided adaptive radiotherapy in cervix cancer patients.


Eligibility criteria:
inclusion criteria: * histological diagnosis of cervix cancer * prescription of radiation treatment to the primary cancer exclusion criteria: * prior radiation treatment to the pelvis

Keywords: image guided adaptive radiotherapy
efficacy study of prednisone priming to treat asian chronic hepatitis b patients

Conditions: Chronic Hepatitis B

Summary: patients with chronic hepatitis b constantly produce the virus in the body. the disease of chronic hepatitis b is the body responding to the virus. use of steroids can adjust this response. after taking steroids, viral production usually increases and liver function tests increase. after stopping steroids, viral production usually decreases. many studies in the past have studied taking a low dose steroid before treating hepatitis b. those studies have shown that low dose steroids help your body to clear the virus. the goal of this study is to improve the liver function by slowing viral growth.

asian patients who are older than 16 years of age and have hbeag-positive chronic hepatitis b and good liver function will be entered in this study. qualified patients also have positive hepatitis b surface antigen (hbsag) for at least 24 weeks before screening, evidence of chronic hepatitis on a baseline liver-biopsy sample obtained within 52 weeks before entry, evidence of hbv dna by any commercial tests at least 4 weeks before screening, an high hbv dna level (at least 20,000 iu/ml) at screening, and a high serum alt level (1.0 to 5.0 times the upper limit of normal) at screening. this study involves experimental use of an approved drug (prednisolone) on chronic hepatitis b patients. patients will be involved in the study for up to 96 weeks from enrollment. there is no external sponsor, commercial sponsor nor federal agency on this study. the study will be conducted only at maimonides medical center, its gi clinic and faculty practice. about 40 subjects will be involved in the study overall. all the subjects will be filled up locally.

Eligibility criteria:
inclusion criteria: this study is seeking patients with the following: * asians older than 16 years of age * hbeag-positive chronic hepatitis b, and * good liver function * positive hepatitis b surface antigen (hbsag) for at least 24 weeks before screening * liver biopsy in the past year showing of chronic hepatitis * blood testing showing hbv dna in the past 4 weeks before screening * blood test showing high hbv dna level (at least 20,000 iu/ml); and * liver function test showing high serum alt level (1.0 to 5.0 times the upper limit of normal). exclusion criteria: * ongoing drug abuse * active alcoholism * coinfection with hepatitis c, hepatitis d, or hiv * presence of other forms of liver disease * use of interferon alfa, thymosin, or antiviral agents with activity against hepatitis b within 24 weeks before randomization * prior lamivudine therapy lasting more than 12 weeks * previous treatment with adefovir dipivoxil * afp level greater than 100 ng/ml * decompensated liver disease * history of ascites requiring diuretics or paracentesis

Keywords: hepatitis b e antigen hbeag-positive chronic hepatitis b
ceribell delirium data collection study

Conditions: Delirium

Summary: this study is designed as a prospective, non-randomized, observational clinical study. the study will collect clinical and rreeg (ceribell eeg) data when monitoring subjects for delirium subtypes. eeg and clinical data will be collected for the development of future software algorithms to assess the presence and severity of delirium.


Eligibility criteria:
inclusion criteria: all must be present * age is 18 years or older * admitted to the intensive care unit (icu) * subject must be fluent in the language in which the delirium assessment is performed exclusion criteria: all must be absent - any condition that prevents use of the ceribell eeg system on the subject for the entire anticipated eeg monitoring period. examples may include: craniectomy with missing bone flap in an area where ceribell eeg electrodes are placed. expected use of continuous clinical eeg for the entire anticipated monitoring period.

Keywords: delirium eeg electroencephalogram
pelvic floor muscle contraction among physiotherapy students before and after "women health" course

Conditions: Pelvic Floor Muscle Weakness

Summary: the study aim is to evaluate the ability to correctly contract pelvic floor muscle among physiotherapy students before and after "women health" course. pelvic floor muscle contraction will be evaluated via transabdominal ultrasound.

physiotherapy students during their studying in the physiotherapy bachelor degree program will be examined. students will be divided into 2 groups according to their year of studying (if they already studied "women health course or not implying 4th year students compared with 1-3 year level students). each participant will be asked to contract the pelvic floor muscles. the assessment of pelvic floor contraction will be measured by measuring bladder displacement via abdominal ultrasound. a curved linear array transducer will be placed in the transverse plane immediately suprapubically over the lower abdomen angled at 15-30 degrees from the vertical. upward movement of the bladder during contraction will be marked as correct contraction. an on screen caliper and measurement tool will be used to measure bladder amount of bladder displacement.

Eligibility criteria:
inclusion criteria: * healthy students * willing to participate in the study exclusion criteria: * has been treated before for pelvic floor rehabilitation * active urinary tract infection * pregnancy * previous abdominal surgeries

Keywords: pelvic diaphragm, physiotherapy students, education
evaluation of the tolerance and safety of a new partly fermented anti-regurgitation infant formula

Conditions: Regurgitation, Gastric

Summary: a randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum in infants with regurgitation.


Eligibility criteria:
inclusion criteria: 1. singleton healthy term infant aged 3 - 13 weeks; 2. gestational age at birth 37- 42 weeks; 3. normal birth weight for gestational age and gender i.e. 10th to 90th percentile compared to the who or local growth charts; 4. infants with regurgitation that are otherwise healthy, based upon the following criteria: 1) regurgitation of 2 or more times per day for 1 or more weeks according to reported history, 2) an indication for the use of ar formula according to the investigator at screening/randomisation. 5. fully formula fed for at least 7 days before screening/randomisation; 6. written informed consent from the parent(s) and/or legally acceptable representative(s), aged ≥ 18 years. - exclusion criteria: * 1. history of retching, hematemesis, aspiration, apnoea, failure to thrive, feeding or swallowing difficulties or abnormal posturing; 2. gastrointestinal infection within 4 weeks prior to randomisation; 3. congenital condition and/or previous or current illness and (or) medication use that could interfere with the main study outcomes according to the investigator; 4. known cow's milk protein allergy, lactose intolerance, or galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients (especially scgos); 5. presence of any other gastrointestinal symptom(s)/disorder(s) that are not functional in nature, as assessed by the investigator's clinical judgement; 6. received any of the following products/medication prior to randomisation: systemic antibiotics, prokinetics, proton pump inhibitors, complementary feeding/weaning within 4 weeks prior to randomisation; 7. incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the parent(s) to comply with the protocol requirements; 8. current participation in another clinical intervention study.
detection of sepsis occurrence by using blood fluorescence

Conditions: Sepsis

Summary: this study adopted a case-control study method to explore a reagent-free, highly sensitive, and frequently screened blood fluorescence metabolite analyzer for sepsis, which can detect the emergence of inflammatory free radicals before organ damage and shorten the diagnosis time of sepsis.

currently, clinical practice lacks an effective screening method for early detection and prediction of sepsis. this gap hinders timely differential diagnosis, leading to severe shock and increased mortality rates. although the qsofa score is highly specific, it is not devoid of false negatives. typically, by the time sepsis is confirmed using the qsofa (≥ 2) and sofa (≥ 2) scores as gold standards, the patient may already be suffering from organ damage, thus escalating the risk of death. early-stage septic patients exhibit a surge in inflammatory free radicals, altering the optical characteristics of their blood compared to that of healthy individuals. based on this, we hypothesize that a blood fluorometer could detect these early changes in septic patients, enabling rapid and accurate diagnosis to mitigate mortality rates. this study will conduct a case-control investigation, collecting blood from both admitted and discharged patients, with the aim of developing a reagent-free, highly sensitive blood fluorescence metabolite analyzer. this device will be capable of frequent sepsis screenings, detecting inflammatory free radicals before organ damage occurs, thereby reducing the time to sepsis diagnosis.

Eligibility criteria:
inclusion criteria: 1. healthy control group: individuals who are physically healthy with no underlying diseases and have not been hospitalized within the past two years. recruitment for healthy volunteers will be conducted through notices and online media. 2. sepsis experimental group: patients with confirmed infections, having qsofa ≥ 2 and sofa ≥ 2, will be screened and confirmed by a physician to meet the inclusion criteria. 3. non-septic severe control group: patients with suspected or confirmed infections, having a sofa score of 1, will be screened and confirmed by a physician to meet the inclusion criteria. exclusion criteria: minors, pregnant, individuals with mental illnesses, and other vulnerable groups.

Keywords: blood fluorescence sepsis early detection